Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1958 1
1989 1
1990 1
1999 1
2011 1
2012 3
2013 4
2014 2
2015 1
2016 4
2017 9
2018 16
2019 17
2020 24
2021 24
2022 23
2023 38
2024 46
2025 36
2026 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for forcade
Search for forcades instead (1 results)
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers RAP, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, Sicre de Fontbrune F, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, van Lint MT, Passweg JR, Marsh JCW, Socié G, Mufti GJ, Dufour C, Risitano AM; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Peffault de Latour R, et al. N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965. N Engl J Med. 2022. PMID: 34986284 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J; Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I). Scherlinger M, et al. Lancet Rheumatol. 2025 Jun;7(6):e434-e447. doi: 10.1016/S2665-9913(24)00377-1. Epub 2025 Mar 26. Lancet Rheumatol. 2025. PMID: 40157379 Review.
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. D'Angelo SP, et al. Lancet. 2024 Apr 13;403(10435):1460-1471. doi: 10.1016/S0140-6736(24)00319-2. Epub 2024 Mar 27. Lancet. 2024. PMID: 38554725 Free PMC article. Clinical Trial.
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Lee JW, et al. Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0. Lancet Haematol. 2023. PMID: 38030318 Clinical Trial.
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
Mohty M, Socié G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kröger N, Stölzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N. Mohty M, et al. J Clin Oncol. 2025 Dec;43(34):3639-3645. doi: 10.1200/JCO-25-00809. Epub 2025 Oct 15. J Clin Oncol. 2025. PMID: 41092247 Free PMC article. Clinical Trial.
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Arrieta-Bolaños E, van der Burg LLJ, Gedde-Dahl T, Robin M, Salmenniemi U, Kröger N, Yakoub-Agha I, Huynh A, Crawley C, Deconinck E, Bulabois CE, Forcade E, Tholouli E, van der Hem JGK, van Balen P, Hoogenboom JD, de Wreede LC, Malard F, Ruggeri A, Fleischhauer K. Arrieta-Bolaños E, et al. Blood. 2024 Oct 17;144(16):1747-1751. doi: 10.1182/blood.2024024351. Blood. 2024. PMID: 39102621 Free article.
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.
Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Adès L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Récher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sébert M. Loschi M, et al. Blood Adv. 2025 Dec 23;9(24):6314-6325. doi: 10.1182/bloodadvances.2025017084. Blood Adv. 2025. PMID: 40924929 Free PMC article.
243 results